The EANM/SNMMI 2019 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma (PPGL) describe the current experts' views on molecular imaging in the era of precision medicine, and contain all of the information needed by nuclear physicians for performing, interpreting, and reporting the results of imaging investigations. This editorial, from a clinician's perspective, describes the first-choice radiopharmaceutical for a particular clinical setting as an important element of the revised guidelines. It also gives new evidence-based data showing the steadily growing role of nuclear imaging in PPGL phenotyping and assessment of their clinical characteristics and outcomes.